While the inhibition of YTHDF1 and/or YTHDF2 in DCs and macrophages have been suggested to be promising anticancer strategy, the influences of such inhibition on the other intracellular molecules and pathways besides those already explored and on cancer cells, other immune cells, and other stromal cells also need to be clarified to further support the therapeutic significance with safety; it would also be important to explore how to precisely deliver the corresponding inhibitory drugs to the specific cell types to minimize the off-target effects. This evidence concerns the gene YTHDF1 and cancer.